{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:24:40Z","timestamp":1772663080695,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106614"],"award-info":[{"award-number":["JP20ck0106614"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D. Since then, development has been promoted in the direction of introducing preoperative chemotherapy, changing post-operative adjuvant chemotherapy according to histological effects, adding ifosfamide as a key drug and strengthening adjuvant chemotherapy. No clinical trials, however, have shown the effectiveness of study treatment, and the improvement of treatment results during that time has been slight, although the JCOG0905 study is now going to verify the effectiveness of introducing ifosfamide for patients who experienced limited preoperative therapeutic effects. We are desperately looking for a breakthrough.<\/jats:p>","DOI":"10.1093\/jjco\/hyab120","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:17:08Z","timestamp":1626434228000},"page":"1493-1497","source":"Crossref","is-referenced-by-count":21,"title":["Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-1070","authenticated-orcid":false,"given":"Hiroaki","family":"Hiraga","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Okayama University Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2021100512320874300_ref1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bmj.2.5758.363","article-title":"Bone sarcoma: treatment by irradiation, amputation, or a combination of the two","volume":"2","author":"Sweetnam","year":"1971","journal-title":"Brit Med J"},{"key":"2021100512320874300_ref2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jama.221.10.1132","article-title":"Doxorubicin in disseminated osteosarcoma","volume":"221","author":"Cores","year":"1972","journal-title":"JAMA"},{"key":"2021100512320874300_ref3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198606193142502","article-title":"The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity","volume":"314","author":"Link","year":"1986","journal-title":"N Engl J Med"},{"key":"2021100512320874300_ref4","first-page":"8","article-title":"Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study","author":"Link","year":"1991","journal-title":"Clin Orthop"},{"key":"2021100512320874300_ref5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.1987.5.1.21","article-title":"Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial","volume":"5","author":"Eilber","year":"1987","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref6","first-page":"421","article-title":"Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients","volume":"71","author":"Pratt","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2021100512320874300_ref7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2003.08.165","article-title":"Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651","volume":"21","author":"Goorin","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","article-title":"Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children\u2019s Cancer Group","volume":"15","author":"Provisor","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.1988.6.2.329","article-title":"Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response","volume":"6","author":"Winkler","year":"1988","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref10","first-page":"115","article-title":"High-dose ifosfamide in advanced osteosarcoma","volume":"69","author":"Marti","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2021100512320874300_ref11","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2000.18.24.4016","article-title":"Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli\/osteosarcoma-2 protocol: an updated report","volume":"18","author":"Bacci","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00776-009-1347-6","article-title":"Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J","volume":"14","author":"Iwamoto","year":"2009","journal-title":"J Orthop Sci"},{"key":"2021100512320874300_ref13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jjco\/hys059","article-title":"The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group","volume":"42","author":"Iwamoto","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2021100512320874300_ref14","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","article-title":"Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 Good Response Randomized Controlled Trial","volume":"33","author":"Bielack","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021100512320874300_ref16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jnci\/djk015","article-title":"Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup","volume":"99","author":"Lewis","year":"2007","journal-title":"JNCI"},{"key":"2021100512320874300_ref17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021100512320874300_ref19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/10\/1493\/40508613\/hyab120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/10\/1493\/40508613\/hyab120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T22:05:31Z","timestamp":1633557931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/10\/1493\/6329817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,7,29]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab120","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,7,29]]}}}